Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TLR3 agonists as immunotherapeutic agents.

× No keyword cloud information.

16 in total

1. Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses.

Authors: Maroof Hasan; Catarina Ruksznis; Yan Wang; Cynthia Anne Leifer
Journal: J Immunol Date: 2011-11-02 Impact factor: 5.422

Review 2. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses.

Authors: Man Yu; Stewart J Levine
Journal: Cytokine Growth Factor Rev Date: 2011-04-03 Impact factor: 7.638

3. Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.

Authors: Matthew C Morris; Katherine E Cooney; Hooman Sedghamiz; Maria Abreu; Fanny Collado; Elizabeth G Balbin; Travis J A Craddock; Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal: Clin Ther Date: 2019-03-28 Impact factor: 3.393

Review 4. Trial watch: Dendritic cell-based anticancer therapy.

Authors: Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2014-12-21 Impact factor: 8.110

Review 5. Henipavirus outbreaks to antivirals: the current status of potential therapeutics.

Authors: Christopher C Broder
Journal: Curr Opin Virol Date: 2012-03-21 Impact factor: 7.090

Review 6. TLR3 plays significant roles against hepatitis B virus.

Authors: Masoud Karimi-Googheri; Mohammad Kazemi Arababadi
Journal: Mol Biol Rep Date: 2014-01-30 Impact factor: 2.316

7. Over-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production.

Authors: Qing-Meng Zhang; Wu-Qi Song; Yu-Jun Li; Jun Qian; Ai-Xia Zhai; Jing Wu; Ai-Mei Li; Jun-Ming He; Jin-Yun Zhao; Xin Yu; Lan-Lan Wei; Feng-Min Zhang
Journal: Virol J Date: 2012-12-19 Impact factor: 4.099

8. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR⁺ head and neck cancer cells.

Authors: Chwee Ming Lim; Ryan Stephenson; Andres M Salazar; Robert L Ferris
Journal: Oncoimmunology Date: 2013-04-29 Impact factor: 8.110

9. Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery.

Authors: Isabelle Bouvier; Hélène Jusforgues-Saklani; Annick Lim; Fabrice Lemaître; Brigitte Lemercier; Charlotte Auriau; Marie-Anne Nicola; Sandrine Leroy; Helen K Law; Antonio Bandeira; James J Moon; Philippe Bousso; Matthew L Albert
Journal: Front Immunol Date: 2011-12-08 Impact factor: 7.561

Review 10. Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis.

Authors: Giulio Podda; Mukanthu Nyirenda; James Crooks; Bruno Gran
Journal: J Neuroimmune Pharmacol Date: 2013-06-28 Impact factor: 7.285

TLR3 agonists as immunotherapeutic agents.